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Abstract
‘‘Use it and improve it, or lose it’’ is one of the axioms of motor therapy after stroke. There is, however, little understanding
of the interactions between arm function and use in humans post-stroke. Here, we explored putative non-linear interactions
between upper extremity function and use by developing a first-order dynamical model of stroke recovery with longitudinal
data from participants receiving constraint induced movement therapy (CIMT) in the EXCITE clinical trial. Using a Bayesian
regression framework, we systematically compared this model with competitive models that included, or not, interactions
between function and use. Model comparisons showed that the model with the predicted interactions between arm
function and use was the best fitting model. Furthermore, by comparing the model parameters before and after CIMT
intervention in participants receiving the intervention one year after randomization, we found that therapy increased the
parameter that controls the effect of arm function on arm use. Increase in this parameter, which can be thought of as the
confidence to use the arm for a given level of function, lead to increase in spontaneous use after therapy compared to
before therapy.
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Introduction
Stroke often leaves patients with predominantly unilateral
motor impairments. Although the affected upper extremity is
often not completely paralyzed, the recovery of upper extremity
function is often achieved solely by compensatory use, i.e., choice
of the less-affected arm [1]. Improving use of the more affected
arm is important however, because difficulty in using this arm in
daily tasks has been associated with reduced quality of life [2].
There is now definitive evidence that intensive task-specific
practice is effective for improving upper extremity function and
use after stroke [3,4,5,6]. Such training reverses, at least partially,
the loss of cortical representation due to lesion through
recruitment of adjacent brain areas in animals [7,8] and in
humans [9]. This reorganization lasts several years [10], and has
been linked to improved performance [11] and increased use of
the affected limb [12]. On the contrary, lack of training has been
associated with further loss of cortical representation [7,13].
Thus, the axiom ‘‘Use it and improve it, or lose it’’ [14], seems
appropriately applicable to the training period, when the
individual is ‘‘forced’’ to use the affected upper extremity. But,
what happens outside of therapy, when the individual is free to
use, or not use, the affected limb? In some individuals, function
and use further improve in the years following therapy [15,16,17]
(see Figure 1A). For other individuals, function and use decrease in
the years following therapy (see Figure 1B). We previously
hypothesized that the repeated decisions to use the affected limb
in daily activities may be a form of motor practice that can lead to
further improvements [15]. Similarly, repeated, failed, attempts to
use the affected limb have been hypothesized to underlie
worsening of the impairment in a process termed ‘‘learned non-
use’’ [18].
In our previous neuro-computational model of stroke recovery,
we attempted to shed light on the interactions between function
and use in general and learned non-use in particular [19]. Our
model contained two independent motor cortices, each controlling
the contralateral arm, with one being affected by stroke. Before
each movement, one motor cortex was selected by an adaptive
decision-making system, tentatively located in cortico-striatal
networks. Arm performance improved via neural reorganization
in the motor cortex, which learned both to minimize directional
errors (via supervised learning) and to maximize neuronal activity
for desired movement directions (via Hebbian learning). Further-
more, the decision to use one limb or the other was made by
comparing the ‘‘action value’’ of each limb in the adaptive
decision-making system. The values for each arm were updated
based on reward prediction errors (via reinforcement learning). If
performance-based rewards were greater than expected, the arm
was chosen more often for this particular movement. Thus, the
model predicted that function of the affected arm depends on prior
use and that, in turn, arm use depends on non-linear competition
between prior functions of the affected and the non-affected arm.
The model also predicted that if spontaneous recovery, or motor
training, or both, brings performance above a certain threshold,
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learning that further bootstraps performance and spontaneous use.
Below this threshold, spontaneous arm use after training decreases
(thus the model exhibits ‘‘learned non-use’’), and compensatory
movements with the less affected hand are reinforced. We
previously provided clinical evidence for such a threshold at the
group level [20].
Here, our principal aim was to test the hypothesis that, in
individuals in the chronic phase post-stroke, function of the
affected arm depends on prior use of that arm and arm use, in
turn, depends non-linearly on function, as predicted from our
previous model. For this purpose we developed a new data-driven
quantitative first-order dynamical model of stroke recovery that links
arm function and use with a small number of parameters, which
can be directly adjusted from actual data. We obtained data on
upper extremity function and use for a two-year period starting
from 3 months or more after stroke from the database of the Phase
III randomized controlled clinical EXtremity Constraint Induced
Therapy Evaluation (EXCITE) trial [3], which aimed at
demonstrating the efficacy of a rehabilitative intervention for
upper extremity. Arm function was derived from the time score of
the Wolf Motor Function Test (WMFT) [21,22] and arm use data
was derived from the Motor Activity Log Amount of Use (MAL
AOU) [23,24]. Because of the sparsity of the data, we used
Bayesian regression to fit the model. In addition, Bayesian
regression allowed us to systematically compare our model with
alternative models to test our hypothesis. We validated the model
by computing the prediction errors of the model with a leave-one-
out method.
Our secondary aim was to investigate whether motor therapy
can change the hypothesized relationship between arm function
and use by examining the model parameters before and after
therapy. Besides improving both function and use, therapy may
increase the confidence to use the arm [25,26]. We thus predicted,
that, the relationship that links arm function to arm use can be
modified by therapy, and that controlling for the level of function,
arm use can increases after therapy compared to before therapy.
Methods
Data for model parameter fit and model selection
In EXCITE, two groups of participants 3 months or more post-
stroke were randomly assigned to either an immediate or a delayed
Constraint Induced Movement Therapy (CIMT) group [3,27,28].
After 3 months, changes in function can be attributed more to
learning and adaptation rather than to significant physiological
modifiers that dominate the initial recovery period. The
immediate group received two weeks of therapy from time Pre1
(t=0) to Post1; the delayed group received two weeks of therapy
after a one-year delay, from Pre2 (t=1 year) to Post2.
The measure of function that we used to develop our model was
the negative of the logarithm of the WMFT time score,
normalized between 0 and 1. The WMFT time score [21,22]
has been used as either a primary or a secondary outcome in more
than 70 published studies including the EXCITE trial. The test
determines the time required for patients with stroke to perform 15
everyday tasks with each upper extremity. Tasks are sequenced so
that the first six tasks involve simple limb movements, primarily of
the proximal musculature; the next nine tasks require manipula-
tion and distal control. The time score is computed by adding the
times of the tasks that the subject can perform within 120 seconds.
For each task that the subject cannot perform, 120 sec are added.
The WMFT time score has good reliability, validity, and no
learning effect [22]. Note that because the more simple tasks can
Figure 1. Longitudinal arm and hand use data (as measured by the MAL AOU test, normalized) for 48 participants of the immediate
group in EXCITE illustrating how use can increase (A), decrease (B), or not change (C) in the 24 months following therapy.
Classification in the three categories was based on the significance of the slope parameter of a linear model fit of use as a function of time, with a
lenient criterion to test the hypothesis that the slope is not different from zero (p,0.25). Use increase category, N=14; Use decrease category, N=12;
No change in use category, N=22.
doi:10.1371/journal.pcbi.1002343.g001
Author Summary
Although, there is now definitive evidence that intensive
task-specific practice is effective for improving upper
extremity function and use after stroke, it is unclear how
individual patients recover from stroke, and how they
respond to therapy. Here, we propose a novel computa-
tional model of stroke recovery to study the time-varying
dynamics of recovery of individuals at least 3 months post-
stroke with mild to moderate impairments. Our model
gives support to one of the axiom of neuro-rehabilitation
‘‘use it or lose it’’. Furthermore, analysis of the model
parameters showed that increase in confidence to use the
affected arm during therapy may affect the dynamics of
recovery. Our long-term goal is to develop and validate a
method based on such dynamical models, to allow
clinicians and patients to make informed decisions about
treatment and potentially determine the critical dose of
motor therapy for an individual patient.
Arm Function and Use in Humans Post-stroke
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time score has a long-tail. The natural logarithm of the WMFT
time score is therefore taken to transform the distribution into a
normal distribution [3]. To readily incorporate the time score of
the WMFT (after logarithm transformation) into our model, we
negated the logarithm transformed WMFT score such that a good
(low) WMFT time score corresponds to good (high) arm function.
We then normalized the range by dividing by the difference
between the highest score and the lowest score in the data set, and
subtracting the lowest score in the data set from each point. Thus,
a normalized score of 1 corresponds to excellent function and 0 to
very poor function.
The measure of arm use that we incorporated to develop our
models was the average MAL AOU score, normalized between 0
and 1. In the MAL AOU [24,29], the participants (or their
caregivers) rate how much the paretic arm is used spontaneously to
accomplish 30 activities of daily living outside of the laboratory.
Each item on the MAL AOU is ranked from 0 (no use) to 5
(normal) via increments of 0.5. Validity and reliability of the MAL
AOU has been established [24]. The MAL AOU has been used
extensively in studies with a few repeated measurements, including
in the EXCITE trial.
Participants were tested with the WMFT and the MAL AOU at
Pre1 (t=0 week), Post1 (t=2 weeks), Pre2 (t=1 year), and Post 2
(t=1 year+2 weeks). All participants were also tested at 4 months,
8 months, 16 months, 20 months, and 24 months. In the
immediate group, because we only studied the participants’
behavior after therapy, we excluded data at Pre1. Furthermore
because little change in function or use is likely to happen within a
2-week-period one year after CIMT for the immediate group [16],
we averaged the data at between Pre2 and Post2 for this group.
Thus, for each subject of the immediate group, a total of 7 data
points were available, each spaced by 4 months (at Post1, 4, 8, 12,
16, 20, and 24 months), as shown in Figure 1. In the delayed
group, we compared the participants’ behavior after therapy to the
behavior before therapy. Because little change in function or use is
likely to happen in two weeks between Pre1 and Post1 for this
group [3], we averaged the function and use data at these two data
points. Thus, for each subject of the delayed group, 4 data points
were available before therapy (at 0, 4, 8 months, and Pre2) and 4
data points available after therapy (at Post2, and 16, 20, and 24
months).
Because of the very limited number of time points in our study,
we only analyzed the data of participants with full data sets, that is,
each participant had a full complement of WMFT and MAL
AOU data. In the immediate group, 48 participants had a full data
set. In the delayed group, 45 participants had a full dataset.
Quantitative models of arm function and use interaction
We investigated the simplest possible model that best accounted
for four essential characteristics of our previous neuro-computa-
tional model [19]: 1) Time varying changes in arm function and
use reflecting the dynamic of stroke recovery. 2) Effect of use on
function, with high use leading to higher future function, and low
use leading to lower future function. 3) Effect of function on
decision to use the arm, with higher function leading to higher
future use, and lower function leading to lower future use. 4)
Decision to use the affected arm or the non-affected arm based on
competition between prior function of the affected and function of
the non-affected arm.
We specifically hypothesized that a first order non-linear
dynamical system, with two equations, can account for the
interactions between arm function and spontaneous use in
individuals post-stroke. The first (state-space) equation updates
the function of the affected arm; the second equation updates the
use of that arm.
Characteristics (1) and (2) above can be encapsulated by the
evolution of arm function at time step t in terms of arm function
and use at the previous time step as:
Faffected(t)~waFaffected(t{1)zwbUaffected(t{1)zwc
where arm function at t, Faffected(t), is updated based on arm
function and use at the previous time step t21, Faffected(t{1) and
Uaffected(t{1), wa is a decay rate, wb a ‘use effect’ rate, and wc a
constant input. Given the very few data points at our disposal
(7 points in the immediate group), it is unlikely however that such
a complex model with 3 free parameters would provide both good
fit and good generalization (See sub-section ‘‘Model fit’’ below).
Although we consider the 3-parameter model above and a simpler
2-parameter model with wc =0 for model comparison (see below),
we take as our reference model the simplest model, the 1-
parameter model given by:
Faffected(t)~(1{w1)Faffected(t{1)zw1Uaffected(t{1), ð1Þ
where w1 is a free parameter. Equation (1) represents a condensed
version of ‘‘Use it and improve it, or lose it’’, in the condition that
0#w1#1: if Uaffected(t) is zero or small, Faffected(t) decreases. If
Uaffected(t) is large, then Faffected(t) increases. The parameter w1
can be considered as a ‘use effect’ rate; the larger this rate, the
greater the effect of spontaneous arm use on function. The term
(12w1) is a decay rate of arm function: with zero use, arm function
would decay exponentially with time constant D/w1, where D is
the time step of 4 months.
Characteristics (1), (3) and (4) above can be encapsulated by the
update of arm use at time step t, Uaffected(t), in terms of arm
function in the previous time step, Faffected(t{1) as:
Uaffected(t)~
1
1zexp(-(w2 Faffected(t-1)-w3))
, ð2Þ
where w2 and w3 are free parameters. Equation (2) is a sigmoidal
equation that arises from common decision-making models in the
reinforcement-learning framework [30], in which the probability
to take an action is computed by comparisons of the values of each
actions, with the action with the highest ‘‘value’’ being the most
probable. Here, we assumed that the ‘‘action value’’ of each limb
is proportional to the function of each limb at the previous time
step. The slope parameter w2 thus controls the sensitivity of arm
function on arm use and can tentatively be considered as a
‘‘confidence parameter’’: for equal function, greater or smaller w2
leads to more or less use, respectively. The parameter w3
encapsulates the function of the non-affected arm Funaffected(t)
together with any non-modeled bias for preferred use of one arm
versus the other, such as arm dominance or side of stroke. We did
not include Funaffected(t) in the model because the average changes
in function of the unaffected arm following therapy are relatively
small compared to the average changes observed in the affected
arm. Among participants of the immediate group the average log
time WMFT scores is 8.6269.78 (SD) for the affected arm, and
1.9960.82 for the unaffected arm. The median percentage change
in the score for the unaffected arm from just after therapy (Post1,
t=2 weeks) to 24 months, normalized by the score of the affected
arm just after therapy, is 23.6% and the interquartile range 7.1%.
By comparison, the median percentage change of the score for the
affected arm from just after therapy to 24 months, normalized by
Arm Function and Use in Humans Post-stroke
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interquartile range 55.5%. We thus considered the function of the
non-affected arm constant over the two years following therapy;
only the function of the affected arm Faffected(t) enters Equation (2)
(henceforth, we drop the subscript ‘‘affected’’).
Note that because of the simple 1-parameter model of function,
arm function converges to the same value as use in the steady state
(although after transformations to the original WMFT and AOU
score, the values would be of course different). This is simply due
to our choice of a single parameter function model, and there is no
reason why this should happen in actual individuals post-stroke.
Nevertheless, our model may still be adequate given 1) that the
variables may not converge to their asymptotic values within two
years because of long-time constants, and 2) the trade-off between
fit and complexity that favors simpler models.
Model fit, immediate and delayed groups
We estimated w1, w2, and w3 from function and use data of the
EXCITE trial participants in both the immediate and the delayed
group. We also aimed at testing our hypothesis of interactions
between arm function and use as encapsulated in Equation (1) and
(2), against a number of alternative hypotheses, as we now
describe.
Because we have only 7 data points (immediate group) and 4
data points (delayed group for each before and after-therapy) for
each arm function and use, we must ensure that the model does
not overfit the data, that is, the model should describe the
underlying relationship, not the random error or noise. Overfitting
generally occurs when a model is excessively complex, such as
having too many parameters relative to the number of data points.
For instance, in frequentist (maximum likelihood) linear regres-
sion, a minimum of 10 or 15 points per predictor is usually
considered necessary.
In contrast, Bayesian regression is the method of choice in our
case, as it does not overfit the data for very small data sets (see [31]
and below for rationale). The Bayesian regression framework has
the additional advantage of allowing principled model comparison
based on the training data alone, that is, without the need for
cross-validation, which ‘‘wastes’’ training data. In light of these
qualities, we used Bayesian regression to determine the parameters
of all the candidate models based on (normalized) WMFT and
MAL AOU data in the immediate group following therapy for
each individual participant (N=48).
Here we illustrate Bayesian regression for our reference model
of Equation (1) and (2). Similar methods are used for the
alternative models. We first reformulated Equation (1) and (2) to
form equations linear in model parameters:
Ft ðÞ {Ft {1 ðÞ ~ Ut {1 ðÞ {Ft {1 ðÞ ðÞ w1 ð3Þ
log
Ut ðÞ
1{Ut ðÞ
  
~w2Ft {1 ðÞ {w3: ð4Þ
We then transformed in a linear regression form:
y1 t ðÞ ~Q1 t ðÞ w1 ð5Þ
y2 t ðÞ ~Q2 t ðÞ w2zQ3 t ðÞ w3, ð6Þ
where (5) and (6) correspond to (3) and (4) respectively. y1 t ðÞand
y2 t ðÞare the dependent (target) variables, representing the left-
hand side of (3) and (4) respectively, and Q1, Q2, and Q3 are basis
functions (Q1~Ut {1 ðÞ {Ft {1 ðÞ , Q2 =Ft {1 ðÞ , and Q3~{1).
Note that we can decouple y1 and y2 for the purpose of model
parameter estimation; hence, we use (6) as an example in the
following discussion.
Using a vector form, Equation (6) gives the regression model
given model parameters:
y~Ww, ð7Þ
where y~ y2 1 ðÞ y2 2 ðÞ ...y2 L ðÞ ½ 
T, where L is the number of
measurements, w~½w2 w3 
T, and W is the design matrix
W~
Q2 1 ðÞ Q3 1 ðÞ
. .
. . .
.
Q2 L ðÞ Q3 L ðÞ
2
6 6 4
3
7 7 5:
We need two consecutive measurements to estimate our regression
model: Therefore L=721=6 for the immediate group, and
L=421 for the delayed group. Hence W is L6M matrix, where M
is the number of model parameters (i.e., M=2 for arm use model
(2)).
Measurements from the EXCITE clinical data contain noise,
and we assume that this noise is Gaussian added to the linear
regression model y. The data distribution z is thus assumed to be
drawn independently from Gaussian distribution with mean
y~Ww and variance b
{1:
z*N zjWw,b
{1   
~
b
2p
   L
2
exp({
b
2
z{Ww ðÞ
T(z{Ww)), ð8Þ
where b is a data accuracy hyper-parameter (inverse of variance).
In Bayesian regression, we treat model parameters as a probability
distribution. We assume that the prior distribution of model
parameters is also independent identically distributed Gaussian.
p wjm0,a{1   
~
a
2p
   M
2 exp({
a
2
w{m0 ðÞ
T(w{m0)), ð9Þ
where m0 is the mean of model parameter, and a the model
accuracy hyper-parameter.
The goal of Bayesian regression is to maximize the Bayesian
model evidence, which is the probability of data distribution, given
the model parameters: p zja,b,m0 ðÞ . Using the sum rule and
product rule of probability from (8) and (9), and taking the
logarithm, we obtain the log of the model evidence (see [31] page
167 for derivation for 0 centered priors, and Supplementary
material: Text S1):
logp zja,b,m0 ðÞ ~
M
2
logaz
L
2
logb{
a
2
m{m0 kk
2
{
b
2
z{Wm kk
2{
1
2
logjAj{
L
2
log 2p ðÞ
ð10Þ
where A~aIM|MzbWTW, and ð11Þ
m~A
{1 am0zbWTz
  
, ð12Þ
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As shown from Equation (S24) to (S26) in Supplementary Material
Text S1, m is actually the mean of the posterior distribution of the
model parameters, and A is the accuracy (inverse of covariance) of
the distribution. Note how m reduces to the frequentist regression
solution for a~0.
Equation (10) illustrates how Bayesian regression implements
a trade-off between data fitting and model complexity. With
larger M (more model parameters), Wm can better approximate
the data distribution z, and the error between z and Wm,
z{Wm kk
2 decreases. On the other hand, because the size M of
vector m also scales up with larger number of parameters, the
regularization term m{m0 kk
2 may increase. Similar trade-offs
are found in (11) and (12) in the form of weighted average
between prior knowledge and data. Note that, since the design
matrix W utilizes all data points, we do not need to spare testing
data points for evaluating model fit, unlike cross-validation (e.g.,
leave-one-out).
We maximized the model evidence in terms of the two hyper-
parameters a, which controls model parameter distribution (9),
and b, which controls data distribution (8). Note that m (11) and A
(12) are also functions of a and b. We used an iterative method
[31], where we fixed m and A in the first step and optimized a and
b, and update them with the new a and b in the second step. We
provide here a summary of the algorithm to compute the model
evidence (see Supplementary material: Text S1 for details).
1. Set m0, and initial a and b
2. Compute a and b using Equation (S21) and (S23) in Text S1
2:1 a/
c
m{m0 kk
2
2:2 b/
L{c
z{Wm kk
2
where c~
P M
i~1
li
azli
and li is i-th eigenvalue of bWTW
3. Update m and A using (11) and (12)
3:1 A/aIM|MzbWTW
3:2 m/A
{1 am0zbWTz
  
4. Repeat 2 and 3 until convergence
5. Set a /a and b
 /b, and compute model evidence (10), and
posterior model parameter distribution, Equation (S24) in Text
S1
Model comparison, immediate group
Our hypothesis of ‘‘Use it and improve it, or lose it’’ is
encapsulated in our reference model of arm function, which
assumes that current arm F(t) function depends on a weighted
sum of previous arm function F(t21) and previous arm use
U(t21). We compared this model with alternative hypotheses in
which F(t) does not depend on use, but only on previous arm
function F(t21) (i.e. use has no effect on function), or
conversely, in which F(t) depends solely on previous use
U(t21), not on previous function. As noted above, our
hypothesis is not specific to the exact model given in Equation
(1), but other models containing a linear combination of F(t21)
and U(t21) also fall under ‘‘Use it and improve it or lose it’’.
Thus, we also considered more complex linear stable models
with 2 and 3 parameters. Table 1 shows the 7 possible models
of function that we considered, with the bold model our
‘‘reference model’’.
Our reference model of arm use assumes that current use of the
affected arm U(t) depends via a sigmoidal function on previous
function of the affected arm F(t21) and a constant representing
the function of the non-affected arm. We compared this model
with alternative models in which U(t) depends linearly on previous
arm function F(t21). In simulations of our previous neuro-
computational model, the values for each arm were updated based
on reward prediction errors at a much higher rate than the update
of performance. Since our time step in the current model is 4
months, it is thus possible that the decisions to use the arm are
updated much faster than performance. We therefore also
compared the model of Equation (2) to models in which the
current arm use U(t) depends on current arm function F(t), either
via a sigmoid or linearly. Table 2 shows the 4 possible models of
use that we considered, with the bold model our ‘‘reference
model’’.
Initial means of the parameter distributions were taken as the
values found with maximum likelihood regression of all entries of
the immediate group, except the weighted average model (bold in
Table 1) with initial mean value of w1 at 1. We reflected our
emphasis on data and lack of prior knowledge by setting the ratio
of the initial values of the prior accuracy a0 and the data accuracy
b0 to a0=b0 =10
23 and choosing almost flat priors with
a0 =10
211, for both the function and use models. Note that these
initial parameter values were taken equal for all subjects. We
verified in simulations that when a0,10
211, the results of model
comparison are qualitatively the same as that presented. We set
b0 =10
28 for model fitting. We also performed a sensitivity
analysis (i.e. a systematic variation) on the initial data accuracy b0
(See Supplementary Figure S1).
The Bayesian model evidence for each model was used to
compare models by computing the Bayes factor (BF), which is the
ratio of model evidence probability of competitive models to the
reference model [32]. Thus, given the model evidence probability
pr zja,b,m0 ðÞ for our reference model and the model evidence
probability for a competitive model pc zja,b,m0 ðÞ , the Bayes factor
is given by BF=pr zja,b,m0 ðÞ /pc zja,b,m0 ðÞ . The Bayes factor has a
role similar to the p-value in frequentist statistics and is used to
accept or reject the hypothesis [33]. If BF,1, there is negative
evidence for the hypothesis, and the hypothesis should be rejected.
If 1#BF,3, the evidence is ‘‘barely worth mentioning’’. If
3#BF,10, there is then substantial evidence for the hypothesis,
and BF=3 is a threshold for accepting the hypothesis similar to
p=0.05 in classical statistics. Then for BF.10, 30, and 100 there
is strong, very strong, and decisive evidence for the hypothesis,
respectively.
To compare the models over groups of subjects, a ‘‘group Bayes
factor’’ can be computed by multiplying the individual Bayes
factors [34]. However, such group Bayes factor is misleading in the
presence of the strong outliers, which are present in our analysis
due to poor convergence of the models for a number of individuals
(as a result of our very limited data set). Therefore, we evaluated
the number of comparisons for which BF.3 for either of the
compared models to compute the ‘‘positive evidence ratio’’, which
serves as a measure of which model is optimal at the group level
[34]. Positive evidence ratios read as x:y, where x is the number of
Arm Function and Use in Humans Post-stroke
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than 3, and y the number of subjects for which the Bayes factor of
the alternative model is greater than 3. For N2(x+y) subjects, no
conclusion can be drawn.
Model fit before and after therapy, delayed group
For this analysis, we hypothesized that motor training in the
EXCITE trial, besides improving function and use, also had a
‘‘meta-learning’’ effect (e.g., [35,36]). According to this hypothesis,
CIMT has an effect not only on arm function and use, but also on
the relationships between function and use. In our model, such
meta-learning would translate to different values of the parameters
w1, w2, and w3 before and after therapy. In particular, we
hypothesized that training increases the confidence to use the arm
for a specific level of function, in which the model translates in an
increase in the parameter w2. Using data from the delayed group
in the EXCITE trial (N=45), we used Bayesian regression for our
reference model of Equation (1) and (2), and we compared the
means of the parameters for each subject before and after therapy.
The initial values of the hyper-parameters were the same as of the
immediate group analysis.
Results
Model selection and fit analyses
We first computed the Bayes factors to test the two hypotheses
encapsulated in Equations (1) and (2). Then we computed the
positive evidence ratio for each model from the individual Bayes
factors. Table 3 shows that our reference arm function model
weighting previous arm function and previous use with a single
parameter is strongly preferred over all other models with 2 or 3
parameters. This is presumably because of the sparsity of data in
our database. Our reference arm function model is preferred over
the model that depends only on previous arm function for 27
subjects out of 48 subjects, For 1 subject this alternative model is
preferred, and for 20 subjects, no conclusion can be drawn.
Similarly, our reference arm function model is preferred over the
model that depends only on previous arm use for 25 subjects. For
5 subjects this alternative model is preferred, and for 18 subjects,
no conclusion can be drawn.
Table 4 shows that our reference use model with sigmoidal
model of arm is strongly preferred over the two linear models.
However, our reference model is not preferred over an alternative
model in which arm use depends on current function; there is
indeed a small advantage to the model that computes use based on
current function. Figure 2 shows examples of fits with our model
for both arm function and use, using the mean parameters for
three subjects in the immediate group. In Figure 2A, both function
and use continue to increase after therapy (mean model
parameters w1 =0.76, w2 =2.98 and w3 =0.42). In Figure 2B,
arm use initially largely decreases post-therapy despite relatively
high function. This subject thus exhibits ‘‘learned non-use’’ (Mean
model parameters w1 =0.14, w2 =3.36 and w3 =3.03). In
Figure 2C, conversely, arm use increases after therapy, while
function is relatively high. Because arm function slightly decreases
in the months following therapy, so does arm use, which reaches
immediately post-therapy levels after 2 years (mean model
parameters w1 =0.19, w2 =3.48 and w3 =1.89). These figures
illustrates the dynamic, nonlinear nature of arm function and use
post-therapy, and how our model adequately captures these
dynamical interactions and provide a reasonably good fit to the
data, although the use model appears to better fit the data than the
function model, and with better fit soon after therapy.
To systematically evaluate the goodness of fit, we trained the
model on 6 of the 7 data points available in the immediate group
and compared the prediction of the model to the actual data point
for testing (thus performing a leave-one-out model fit). Note that
we kept the first and the 7th point, since we used them as an initial
and final value of our model. Table 5A shows the average absolute
errors of prediction among subjects of the immediate group. The
average absolute errors of all 2
nd to 6
th leave-one-out prediction
errors were 0.16 for arm function and 0.091 for arm use in the
range between 0 and 1. The models thus reasonably fit the data,
especially in the first year after therapy, although the prediction
errors of the use model are lower than those of the function model
overall (p,0.0001, t-test). As a comparison, the average absolute
errors of randomized models were 0.22 for arm function and 0.26
for arm use (Table 5B). Here, the randomized model generates
predictions points from randomly selected subject at the
corresponding time step. A repeated measure ANOVA confirmed
that mean prediction errors of the proposed arm function model
are smaller overall than those of the randomized arm function
model (p=0.01), although the prediction errors in the proposed
model increase with time (model6time interactions: p,0.0001.
One way repeated ANOVAs, effect of time, proposed function
model: p,0.0001, randomized function model p.0.1). Similarly,
the prediction errors of the proposed arm use model are smaller
overall than those of the randomized arm use model overall
(p,0.001, no model6time interactions; p.0.5).
Model parameter analysis
Histograms of the mean parameters w1, w2, and w3 for the
models of Equation (1) and (2) are shown in Figure 3. Because of
Table 2. Model comparison candidates for predicting arm
use U(t).
Regressors Models
F(t) w2F(t)+w3
F(t21) w2F(t21)+w3
F(t) 1/(1+exp[2(w2 F(t)2w3)])
F(t21) 1/(1+exp[2(w2 F(t21)2w3)])
doi:10.1371/journal.pcbi.1002343.t002
Table 1. Model comparison candidates for predicting arm function F(t).
Regressors 1 parameter model 2 parameters model 3parameters model
F(t21) waF(t21) waF(t21)+wc –
U(t21) wbU(t21) wbU(t21)+wc –
F(t21) and U(t21) (12w1)F(t21)+w1U(t21) waF(t21)+wbU(t21) wa F(t21)+wbU(t21)+wc
doi:10.1371/journal.pcbi.1002343.t001
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exhibit adequate convergence of the model parameter distribu-
tions for all subjects; that is, the parameter distributions were
relatively flat for some subjects. In a first approximation, we
defined good convergence as follows: the standard deviation of the
final parameter distributions after convergence should be less than
one standard deviation of the distributions of the parameters
means. This criterion resulted in the following cut-off standard
deviations: 0.316 for w1; 6.38 for w2 , and 3.67 for w3. As shown in
Figure 3, all negative mean parameters w1 were removed after
applying this criterion. Thus, for all 27 subjects with good
convergence of the Bayesian regression for the function model, the
mean parameter w1 was positive and in the range [0, 1], with
median 0.64. This indicates a positive effect of arm use on the
previous time step upon arm function at the next time step.
Similarly, mean parameters w2 and w3 with large absolute
values were removed by the cut-off procedure. The median of the
mean of w2 for the 32 subjects with good convergence was 2.20.
The median of the mean of w3 for the 33 subjects with good
convergence was 1.40. Positive parameters w2 indicate that arm
function has a positive effect on arm use, as hypothesized. Positive
parameter w3 indicates competition between function of the
affected limb and (constant) function of the non-affected limb, as
predicted by models of decision-making based on comparisons of
‘‘values’’. Note that we verified with surrogate data derived from
the model that our Bayesian regression method can indeed retrieve
the parameters of the original model (see Supplementary material:
Text S2 and Figure S2).
Effects of therapy on model parameters
We then examined whether CIMT had an effect on the model
parameters in the delayed group by comparing before and after
therapy models. Before-therapy model parameters were trained
with arm function and use in the year before therapy. After-
therapy model parameters were trained with arm function and use
in the year after the therapy period. The standard deviation cut-off
values were the same as above, and only parameters with good
convergence before and after therapy were analyzed.
Among the three model parameter means, only the means of w2
was significantly different between before and after and therapy
(Figure 4B, mean of w2 before therapy 2.9560.32; after-therapy
4.5860.49; p=0.041; N=22; 2-tailed pair t-test). There was no
difference in w1 (Figure 4A, before-therapy 0.75960.044; after-
therapy 0.82560.036; p=0.55; N=27; 2-tailed pair t-test) and in
w3 (Figure 4C, before-therapy 2.2160.16; after-therapy
2.1060.20; with p=0.54, N=28, 2-tailed pair t-test).
Model simulations
Our previous neuro-computational model of stroke recovery
[19] exhibited non-linear and bi-stable behavior of stroke
recovery: the model predicted that if natural recovery, motor
training or both, brings performance above a certain threshold,
training can be stopped, as the repeated spontaneous arm use
provides a form of motor learning that further bootstraps
performance and spontaneous use.
Here, we simulated our model made of Equation (1) and (2) to
study whether the simplified model of the present study also
contained such threshold and bi-stable behavior, and to study the
effect of the increase of the ‘‘confidence’’ parameter w2 from
before to after therapy, with the simplifying assumptions that
therapy does not increase function and use. For this purposes
we performed a parameter sensitivity analysis using the continu-
ation and bifurcation toolbox Matcont (http://sourceforge.net/
projects/matcont/).
The sensitivity analysis of Figure 5B shows that for w3#3 and
low values of w2, asymptotic function and use are low. However,
by increasing w2, therapy can ‘‘move’’ the participants from one
low attractor to a high attractor region, exhibiting convergence to
different arm function values, as shown in simulation results of
Figure 5 A and B. Thus, if therapy increases the confidence to use
the arm, the greater spontaneous arm use will lead to greater
function, in a virtuous cycle (Figure 5A, w2 =4 or w2 =5). In
contrast, for a low value of the parameter w2, the simulated patient
is in a vicious cycle and use decreases (as in Figure 5A for w2 =3).
Because of competition between function or each arm in
computing use, high values of w3 lead to greater non-use
compared to smaller values of w3 (See left side of Figure 5B).
This is illustrated by comparing arm use for the two subjects in
Figure 2B and 2C. The main difference in parameters between the
subjects of Figure 2B and 2C is the value of w3. Because w3 is
relatively large in 2B, arm use decreases to low level; in contrast
use stays relatively high in 2C. However, for w3.3, a sufficient
increase in the parameter w2 will bring the system in a truly bi-
stable mode. Depending on the initial condition (i.e. values of F(t)
and U(t) just after therapy), function and use can either remain
near low values or near high values delimited by the low Limit
Point (LP) and high LP in the Figure 5B. Thus, the model exhibits
a ‘‘threshold’’ in function, as we proposed in our previous work
[19,20].
Table 3. Positive Evidence Ratio for function model (48 subjects, immediate group).
Regressors 1 parameter model 2 parameters model 3parameters model
F(t21) 27:1 46:1 –
U(t21) 25:5 45:2 –
F(t21) and U(t21) w1U(t21)+(12w1)F(t21) 47:1 47:1
The models correspond to the models of Table 1.
doi:10.1371/journal.pcbi.1002343.t003
Table 4. Positive Evidence Ratio for use model (48 subjects,
immediate group).
Regressors Models
F(t) (linear) 38:2
F(t21) (linear) 38:2
F(t) (sigmoidal) 14:19
F(t21) (sigmoidal) 1/(1+exp[2(w2 F(t21)2w3)])
The models correspond to the models of Table 2.
doi:10.1371/journal.pcbi.1002343.t004
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Stroke recovery is, by definition, a time-varying process.
Although our dynamical ‘‘state-space’’ model naturally accounts
for the time-varying nature of stroke recovery, this paper
represents, to our knowledge, the first effort to use approach to
quantitatively model recovery of individuals post-stroke. The
stroke recovery model proposed here depicts a time-evolving
process with interactions between arm function and use. The
model, which is composed of two sub-models, one that updates
arm function (Equation (1)) and the other that updates arm use
(Equation (2)), has only three free parameters, which were
estimated with repeated measurements of upper extremity
function and use obtained in a phase III randomized controlled
clinical trial, the EXCITE trial.
For a majority of the participants in the immediate group of the
EXCITE trial that we studied, arm function depends both on
prior function and prior use. Presumably because of the very
limited amount of data that penalizes models with more
parameters, the preferred arm function model performs a
weighted average of previous arm function and use with a single
parameter. This model is preferred for 27 subjects out of 48 over a
competitive model in which arm function is not dependent on
previous use, and is preferred for 25 subjects out of 48 over a
model in which function is solely based on use. The alternative
models are preferred for 1 and 5 subjects respectively; for the
remainder of the subjects, no conclusion can be drawn.
Furthermore, parameter analysis showed a positive effect of arm
use at the previous time step upon arm function at the current time
step, thus truly capturing the phenomenon of ‘‘Use it and improve
it, or lose it’’ for a majority of the participants we studied.
Although this phenomenon may be taken for granted by stroke
rehabilitation specialists, this is, to our knowledge, the first
systematic demonstration of the effect of the upper extremity use
on changes in function and vice-versa in stroke recovery in
individual subjects (in our previous study [20] we only study this
effect of function immediately following therapy upon future use at
the group level).
We further showed that for the large majority of the participants
we studied, models of spontaneous arm use based on a sigmoidal
dependency of arm function are preferred over linear models. This
result indicates that the non-linear dependency of use on function
has a strong effect on the fit of the use data. Furthermore,
parameter analysis showed that arm function has a positive effect
on arm use with competition between function of the affected limb
and (constant) function of the non-affected limb, as predicted by
models of decision-making based on comparisons of ‘‘values’’ e.g.
[37]. Time has a lesser effect: Our reference model of Equation (2)
Table 5. Prediction errors at different time points (leave-one-out points) after therapy.
A: Prediction error of proposed model
Leave-one-out point 2 (4 months) 3 (8 months) 4 (12 months) 5 (16 months) 6 (20 months) Ave.
Average absolute error (Arm function) 0.097 0.12 0.18 0.18 0.19 0.16
Average absolute error (Arm use) 0.055 0.080 0.088 0.12 0.12 0.091
B: Prediction error of randomized model
Leave-one-out point 2 (4 months) 3 (8 months) 4 (12 months) 5 (16 months) 6 (20 months) Ave.
Average absolute error (Arm function) 0.23 0.22 0.21 0.22 0.21 0.22
Average absolute error (Arm use) 0.25 0.22 0.26 0.27 0.31 0.26
doi:10.1371/journal.pcbi.1002343.t005
Figure 2. Examples of model fit for upper extremity function and use over 24 months post therapy for three subjects in the
immediate group using the model of Equation (1) and (2) in the main text (and corresponding equations in bold fonts in Table 1
and 2). The blue lines show the actual data. The red lines are generated by the model with the mean model parameters, trained with 7 data points.
(A) Both arm function and use improve (mean model parameters w1 =0.76, w2 =2.98 and w3 =0.42) (B) Arm function is more or less constant, while
arm use shows ‘‘non-use’’ (mean model parameters w1 =0.14, w2 =3.36 and w3 =3.03). (C) Arm function slightly decreases, while arm use rises after 4
month and keeps the level (mean model parameters w1 =0.19, w2 =3.48 and w3 =1.88). See how the model fit is in general good for use over the 24
months and for function in the first year but then is getting worse for function in the second year (see Table 3 and 4 for a systematic evaluation of
model fit).
doi:10.1371/journal.pcbi.1002343.g002
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preferred for 14 subjects over a model in which use depends on
current function F(t)). Contrarily this alternative model is preferred
for 19 subjects over the reference model (no conclusion can be
drawn for the remainder 15 subjects). This inconclusive effect of
time on arm use suggests that update of the arm choice
(presumably via the learning of ‘‘values’’) is fast compared to the
update of arm function.
Our previous neuro-computational model of stroke recovery
[19] exhibited bi-stable behavior of stroke recovery. Here, our
simpler data-driven model also exhibits a bi-stable behavior,
although for relatively large values of the parameters w2 and w3 of
the use model (see Figure 5B). However, even for lower value of
the parameters (around the mean of the estimated parameters)
therapy can, by increasing the parameter w2, ‘‘move’’ the
participants from one low attractor to a high attractor region
shown in simulation results of Figure 5A. This simulation of the
model made of Equation (1) and (2) illustrates the effect of the
increase of the ‘‘confidence’’ parameter w2 from before to after
therapy, with the simplifying assumptions that therapy does not
increase function and use. Simulations show that if therapy
increases confidence to use the arm, the greater spontaneous arm
use will lead to greater performance, in a virtuous cycle (Figure 5,
w2 =4orw2 =5). In contrast, for a low value of the parameter, the
patient is in a vicious cycle and use decreases (as in Figure 5 for
w2 =3). Unfortunately, because of the limited data set, the
sustainability of this increase in confidence in participants of the
EXCITE trial is unclear. Since the median w2 post-therapy in the
immediate group (2.20) is inferior to the median w2 post-therapy
in the delayed group (3.90) such increase may be relatively short-
lasting post-therapy.
In sum, our results suggest that learned non-use results, at least
in part, from three non-mutually exclusive factors: 1) a decrease in
function of the affected arm; 2) a relative increase in function of
the non-affected arm (if for instance stroke affects the right arm
and the right-hand dominant subject is learning how to use her left
arm); 3) reduced ‘‘confidence levels’’ in using the arm for a given
function (as a result of spilling a hot coffee on someone else for
instance). Since our study is only a model of changes in behavior,
we can only speculate on the causes of non-use at the neural level.
Reduced use may lead to contraction of motor cortical maps
leading to decreased performance and further reduced use [19];
contrarily forced use (i.e. practice) may lead to map expansion and
increase performance [7]. If such improvements in function
together with confidence levels are sufficient, then use of the
affected arm in daily activities may increase sufficiently such that
function will improve spontaneously, effectively reversing non-use,
as shown by our simulations in Figure 5. The median of w1 across
Figure 3. Histograms of the means of parameters w1, w2, and w3 of the model estimated with data of the immediate group in the
EXCITE trial. Blue and Red: subjects with all estimated mean parameters. Blue: subjects with mean parameters after application of convergence
criteria (see Results). The numbers N’s indicate the numbers of subjects with good convergence for each parameter. Note that for w1, the means of all
parameters with good convergence are in the range [0; 1] supporting the ‘‘Use it and improve it, or lose it’’ model. Similarly, for w2, the means of most
parameters with good convergence are positive, supporting an actual influence of function on use (Refer to Equation (1) and (2) in Methods for the
role of these parameters in the model).
doi:10.1371/journal.pcbi.1002343.g003
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months, this is equivalent to a median time constant of forgetting
of 1/0.64*4 months=6.25 months. This appears reasonable in
light of the long-lasting cortical reorganization after training, e.g.
[10].
Our model assumes the existence of independent measures of
arm function and use across individuals at specific times. So does
the MAL AOU reflect arm use that does not depend on arm
function? We found a moderate but significant correlation
(r=0.58, p,0.0001) between the normalized MAL AOU vs.
WMFT at t=0 for all 93 patients (48 in immediate and 43 in
delayed group). However, there is no correlation between arm
function and use for those 54 patients with medium to low function
(normalized WMFT,0.5, r=0.10, p=0.45). For this sub-group,
normalized MAL AOU ranges between 0 and 0.64. This indicates
that, within this sub-group, some patients have relatively high use
with low function, and vice-versa, and that function and use are
independent variables across subjects. Model comparisons for this
sub-group of subjects with medium to low function still largely
favor our hypothesized models over competitive models (See
Supplementary material: Text S3).
The results of the present study need to be replicated with to-be-
developed databases that contain dozens of repeated measure-
ments of upper extremity function and use before, during, and
after therapy. In particular, our model provides only ‘‘substantial’’
(in a Bayesian model comparison terminology) evidence for the
‘‘use and improve it or lose it’’ hypothesis for a majority but not for
all the EXCITE participants we studied. Because of the sparcity of
the data, the models did not fit the data in a satisfactory manner
for large subgroups of subjects, and no conclusion can be drawn
for these subjects. Furthermore, the predictions from our model,
quite accurate in the first year, became worse with time across
subjects (See Table 5). A possible interpretation of this result is that
the influence of function on use and vice versa is stronger soon
after therapy, but that this influence is reduced due to the myriad
of other un-modeled factors that influence use after stroke (the
patient could for instance go back to work, start to exercise, hire a
caregiver, etc., all of which could affect the rate of recovery). Thus,
our model is currently best viewed as a prototype against which
one can develop further time dependent models of stroke recovery.
Future models, based on a richer longitudinal data set of arm
function and use, including measurements just after the stroke, and
that include neural measurement variables such as lesion size,
location, excitability of the corticospinal tract etc., might better
characterize the time course of stroke recovery. Our assumptions
of two independent cortices, equal roles of each arm, and pure uni-
manual actions are also clear oversimplifications. Also, while
motor (re-) learning after stroke can be understood at least in part
as practice-dependent reduction of kinematic and dynamic
performance errors [38], no such error data were available in
our data set, and we therefore did not include a corresponding
error-based (supervised) learning term in this simplified model
(unlike in our previous model [19]). Instead, the present model
only includes a trivial form of unsupervised learning in the update
of arm function, and a degenerated form of reinforcement
learning, with ‘‘values’’ simply equal to functions. Finally, our
model cannot predict the time course of spontaneous recovery in
the acute phase post-stroke. Here again, more longitudinal data
points, including early after stroke, are needed for viable
extensions of the model.
Nonetheless, our model, although preliminary and despite its
important limitations, is a first step in the direction of the
Figure 4. Effects of therapy on mean model parameters for participants of the delayed group in the EXCITE trial. A. Effect on w1.B .
Effect on w2. C. Effect on w3. Only the mean parameter w2 of equation 2 varies from before (Be) to after (Af) therapy. This parameter controls the
effect of function on use for the affected arm. The horizontal line in B indicates p,0.05.
doi:10.1371/journal.pcbi.1002343.g004
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time course of recovery post-stroke. Our long-term goal is to
validate and test a method based on such dynamical models to
compute the dose of arm and hand motor therapy for individual
patients and provide treating therapists with such a method to be
used in the clinic. A well-validated model of upper extremity
recovery that generates accurate predictions of long-term use and
performance, and the confidence intervals of the predictions, could
be highly valuable because the clinician, patient, or provider (if
applicable) will be able to make informed decisions about
treatment and potentially determine the critical dose of motor
therapy for an individual patient. If for instance the model predicts
that no amount of recovery can increase use, rehabilitation may be
in ‘‘vain’’, and compensatory strategy should be emphasized. On
Figure 5. Computer simulations of arm function showing dependence on model parameters. A. Simulations of the effect on use after
hypothetical changes in the confidence parameter w2 as a result of therapy. Initial parameters values: w1 =0.6, w2 =3, w3 =3. For simplicity, we
assumed here that therapy has only an effect on the parameter w2 and not on use and performance (which it did in actual participants of the EXCITE
trial [3]). The increase in parameter w2 from before to after therapy parallels the increase in this parameter in the delayed group of the EXCITE trial
(see Figure 4). B. Parameter sensitivity analysis showing the asymptotic value of arm function F as a function of parameter w2 for a number of values
of w3. LP: limit point. The line labeled w3 =3 is generated by the same model as in A. For values of w3.3 the system behavior exhibits a non-stable
range between the two limit points. For w3 =3.5 and w2 =5 for instance, arm function F converges to either a low or a high value.
doi:10.1371/journal.pcbi.1002343.g005
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validated and accurate model could be used to determine
minimally effective dose of therapy to maximize the benefit/cost
ratio of therapy.
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Figure S1 Sensitivity analysis of the initial value of the data
accuracy bo for model of arm function (A), and model of arm use
(B). For this analysis, the group median of the log evidence
probability among all subjects was used to represent each model
performance; we then compared the model by computing a Bayes
factor with the group median evidence probabilities. The x axis is
the range of b0 in the power of 10 and y axis is the group median
of log Bayes factor for each model. Our reference model is
Equation (1) for arm function, and Equation (2) for arm use; see
the Table 1 in the main text for the other model entries. We varied
bo (10
28ƒb0ƒ10
23), with fixed a=10
211. The Bayes factor
BF=3 is shown by the black dashed lines in log scale. A:
Sensitivity analysis of bo for arm function model. The bluish color
lines correspond to the models of the 1
st row of table 1, which are
regression models with F(t21) regressor. The light blue color line
shows a model with a single parameter, and the dark blue color
line shows a model with two parameters. Similarly, the grayish
color lines correspond to the models of the 2
nd row of Table 1 with
regressor U(t21). The reddish lines correspond to the models of
the 3
rd row (with regressor F(t21) and U(t21)). The darker lines
have the more number of model parameters. This graph shows
that our reference model outperforms the others, although the
differences with some models are barely worth mentioning in a
small range. B: Sensitivity analysis of bo for arm use model. The
bluish color lines correspond to the linear regression models. Light
blue is with regressor F(t), and dark blue with regressor F(t21).
The reddish color lines correspond to the sigmoidal regression
models with regressor F(t) (light red) and with regressor F(t21)
(dark red). This figure shows that for all b0,10
21, the two
sigmoidal arm use model largely outperform the linear models,
with little differences between the sigmoidal models on one hand,
and the linear models on the other hand.
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Figure S2 Histograms of model parameter derived from
surrogate data as described in Text S2. These histograms of the
model parameters trained by surrogate data sets (2700 datasets for
arm function and 2900 datasets for arm use) compare favorably
with those derived from actual data in Figure 3. For more detail of
surrogate data set, please refer to Text S2.
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Table S1 Positive evidence ratio of the simulation as described
in Text S2. This table shows strong evidence that our proposed
model performs better than the others on the surrogate data set
(2700 datasets for arm function and 2900 datasets for arm use).
For more detail of surrogate data set, please refer to Text S2.
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Table S2 A Positive evidence ratio of arm function for subjects
with medium to low arm functions, as described in Text S3. This
table shows model comparison results of arm function for subjects
with medium to low arm function (normalized WMFT,0.5,
N=22). Model comparisons for this sub-group of subjects with
medium to low function still largely favor our hypothesized models
over competitive models.
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Text S1 Bayesian regression and model parameter optimization.
Detailed derivation for Bayesian regression and optimization with
respect to model parameters are provided.
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Text S2 Simulations with surrogate data. Numerical simulations
are conducted to show that our inference procedure is able to
identify which model the data came from reliably (i.e., that the
model comparison works), and to recover the parameters of the
true underlying model well (i.e., that the model fitting works).
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Text S3 Model comparison for subjects with medium and low
WMFT scores.
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